Commercial Businesses
Research Companies
Pazopanib Hydrochloride
GMP API grade material | Ph EUR compliant | Supply according to GDP | Trusted European API Partner
Pazopanib Hydrochloride
MedicaPharma is your trusted source of top-quality Pazopanib Hydrochloride (HCL) manufactured in accordance with Good Manufacturing Practices (GMP).
MedicaPharma is a reputable API distributor that supplies global pharmaceutical customers such as hospitals, compounding pharmacies, and universities according to Good Distribution Practices (GDP) regulations.
We support you with an extensive range of niche APIs produced by GMP-certified manufacturers worldwide.
- Supply according to GDP regulations
- Global network of over 400 GMP Manufacturers
- Pharmaceutical chemicals (GMP) and more
MedicaPharma Serves Leading Global Healthcare and Research Organizations
We are a trusted partner to various organizations and commercial businesses across multiple sectors in the healthcare industry.
About Pazopanib
Pazopanib HCL is an anti-cancer compound approved for renal cell carcinoma and soft tissue sarcoma. It is a selective multi-targeted receptor tyrosine kinase inhibitor that inhibits angiogenesis and blocks tumour growth.
Regulatory Approval
Numerous regulatory agencies have approved Pazopanib HCL worldwide for use as a treatment for advanced soft tissue sarcomas and advanced/metastatic renal cell carcinoma. The US Food and Drug Administration (FDA) granted approval in 2009, followed by the European Union’s European Medicines Agency (EMA) in 2010. The United Kingdom’s Medicines and Healthcare Products Regulatory Agency approved the compound in 2010, followed by Australia’s Therapeutic Goods Administration later that year. The drug is subsidized in Australia under the Pharmaceutical Benefits Scheme (PBS) and in New Zealand by Pharmac.
Pazopanib HCL Clinical Studies
Clinical studies of Pazopanib include:
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
This phase 3 randomized trial compared the efficacy and safety of pazopanib and sunitinib for patients with clear-cell, metastatic renal-cell carcinoma. The trial recruited 1110 patients, with half receiving pazopanib (800 mg once daily) and the other half receiving sunitinib in 6-week cycles (50 mg once daily for four weeks. Both cohorts followed the treatment with a two-week drug-free period.
The study’s primary endpoint was survival without disease progression and aimed to demonstrate the noninferiority of pazopanib compared to sunitinib. Results from the study showed that overall survival was similar for both treatments, suggesting that pazopanib was non-inferior to sunitinib. Side effects varied, where patients treated with sunitinib experienced higher incidences of fatigue, thrombocytopenia, and hand-foot syndrome. Concurrently, after a six-month assessment, patients treated with pazopanib had a higher incidence of increased alanine aminotransferase levels and less pain in the mouth, throat, hands, or feet.
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial
This phase 3 study, funded by GlaxoSmithKline, examined the effect of pazopanib in patients with metastatic non-adipocytic soft-tissue sarcoma exhibiting progression-free survival after failing to respond to standard chemotherapy. The study involved 369 patients divided into two cohorts where 246 received pazopanib and 123 received a placebo, and the primary endpoint was progression-free and overall survival.
Results of the study suggested that patients treated with pazopanib had a longer progression-free survival rate with a median of 4.6 months when compared to 1.6 months for those on the placebo. However, researchers found no difference in overall survival for both groups.
How Pazopanib HCL Works
Pazopanib is a multiple kinase inhibitor. Also known as a multi-kinase inhibitor or multi-target kinase inhibitor, a multiple kinase inhibitor simultaneously targets and inhibits the activity of multiple protein kinases.
Multiple protein kinases are grouped enzymes that can phosphorylate – a process where a phosphate group of one phosphorus atom and four oxygen atoms are added to a molecule. This process regulates various cellular functions within cells by regulating processes, including cell growth, proliferation, and differentiation.
Abnormal kinase activity is typically connected to diseases such as cancer and inflammatory conditions. Pazopanib works to limit cancerous conditions by inhibiting this mechanism of action to prevent tumor growth.
Why MedicaPharma
We are committed to providing our clients with top-quality products, manufactured to the highest standards and backed by superior customer service.
Countries and jurisdictions may have varying regulatory requirements, with poor enforcement of relevant rules and regulations. There may be accountability and transparency issues associated with manufacturing and distribution, which increases your risk of receiving non-compliant products.
All MedicaPharma APIs are checked within a closed GDP logistics circuit comprising ingoing and outgoing checks to ensure optimal quality and supply of the right material.
Leverage Our Network of 400+ GMP Manufacturers | Access High-Quality Chemicals Produced to GMP Standards | Experience Superior Sales and Support Services |
MedicaPharma partners with over 400 leading global producers to supply hospitals, pharmacies, research facilities, and educational institutions. | All our products are produced in regulated, GMP-compliant facilities and shipped with original documentation. No repacking or relabeling. | MedicaPharma is committed to providing trust, accountability, and transparency. We guarantee our products and support you from start to finish with first-in-class customer service. |
Get a Pazopanib Quote
Obtaining your desired quotation from MedicaPharma is easy; simply complete the form below to begin processing your quote request.
"*" indicates required fields
"*" indicates required fields
Frequently Asked Questions
Pazopanib, a multitargeted tyrosine kinase inhibitor, blocks protein kinase activity. Protein kinases are enzymes that play a critical role in cell signaling pathways. Pazopanib specifically inhibits the activity of receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases involved in cell growth, proliferation, and new blood vessel formation (angiogenesis).
The choice of pazopanib versus sunitinib depends on the patient’s evaluation and the healthcare provider’s recommendation. Both drugs are multitargeted tyrosine kinase inhibitors with similar efficacy in terms of progression-free survival and overall survival. However, in some trials, pazopanib was shown to be non-inferior to sunitinib in terms of the study’s primary endpoint (progression-free survival).
MedicaPharma, an established EU-based API distributor, supplies high-quality pazopanib HCL to pharmacies, hospitals, research, and educational institutions. Click here for a free quote.
GMP (Good Manufacturing Practices) and GDP (Good Distribution Practices) are quality assurance systems essential to the safety of products produced by the pharmaceutical industry. GMP guidelines typically cover the manufacturing processes while GDP governs how the products are transported and delivered.
Recommended articles
